Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma

By afschroeder • October 3, 2026

Johnson NA, Lavie D, Borchmann P, Gregory GP, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Marceu West R, Pillai PM, Marinello P, Timmerman JM. Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma. Blood Adv. 2026 Oct 2:bloodadvances.2025018506. doi: 10.1182/bloodadvances.2025018506. Epub ahead of print. PMID: 42826707.

Tags: Hematology/Oncology, Publications

Related Posts

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, Bixby D, Chai-Ho W, Stahl M, Yee KWL, Stevens D, Ito S, Reynolds[...]

Psychosocial burden in cancer survivors

Ganz PA. Psychosocial burden in cancer survivors. Nat Rev Cancer. 2026 Oct 1. doi: 10.1038/s41568-026-00986-0. Epub ahead of print. PMID: 42823480.

Delta-9-tetrahydrocannabinol alleviates inflammation by modulating immune responses in LPS-induced murine inflammation model

Tomer S, Harding J, Wang L, Kedia N, Cook E, Le V, Platt C, Le J, Tien N, Patalay K, Langfelder P, Yang XW, Zhang[...]